» Articles » PMID: 35055416

Clinical Management of Chronic Pelvic Pain in Endometriosis Unresponsive to Conventional Therapy

Overview
Journal J Pers Med
Date 2022 Jan 21
PMID 35055416
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although several treatments are currently available for chronic pelvic pain, 30-60% of patients do not respond to them. Therefore, these therapeutic options require a better understanding of the mechanisms underlying endometriosis-induced pain. This study focuses on pain management after failure of conventional therapy.

Methods: We reviewed clinical data from 46 patients with endometriosis and chronic pelvic pain unresponsive to conventional therapies at Puerta de Hierro University Hospital Madrid, Spain from 2018 to 2021. Demographic data, clinical and exploratory findings, treatment received, and outcomes were collected.

Results: Median age was 41.5 years, and median pain intensity was VAS: 7.8/10. Nociceptive pain and neuropathic pain were identified in 98% and 70% of patients, respectively. The most common symptom was abdominal pain (78.2%) followed by pain with sexual intercourse (65.2%), rectal pain (52.1%), and urologic pain (36.9%). A total of 43% of patients responded to treatment with neuromodulators. Combined therapies for myofascial pain syndrome, as well as treatment of visceral pain with inferior or superior hypogastric plexus blocks, proved to be very beneficial. S3 pulsed radiofrequency (PRF) plus inferior hypogastric plexus block or botulinum toxin enabled us to prolong response time by more than 3.5 months.

Conclusion: Treatment of the unresponsive patient should be interdisciplinary. Depending on the history and exploratory findings, therapy should preferably be combined with neuromodulators, myofascial pain therapies, and S3 PRF plus inferior hypogastric plexus blockade.

Citing Articles

Registration and characteristics of clinical trials on traditional Chinese medicine and natural medicines for endometriosis: a comprehensive analysis.

Zhao Y, Wang Y, Xue Z, Weng Y, Xia C, Lou J Front Med (Lausanne). 2024; 11:1432815.

PMID: 39564497 PMC: 11573583. DOI: 10.3389/fmed.2024.1432815.


Anatomo-physiological basis and applied techniques of electrical neuromodulation in chronic pain.

Guzzi G, Della Torre A, Bruni A, Lavano A, Bosco V, Garofalo E J Anesth Analg Crit Care. 2024; 4(1):29.

PMID: 38698460 PMC: 11064427. DOI: 10.1186/s44158-024-00167-1.


Understanding the Female Physical Examination in Patients with Chronic Pelvic and Perineal Pain.

Pereira A, Fuentes L, Almoguera B, Chaves P, Vaquero G, Perez-Medina T J Clin Med. 2022; 11(24).

PMID: 36556104 PMC: 9783077. DOI: 10.3390/jcm11247490.

References
1.
Ferrero S, Evangelisti G, Barra F . Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018; 19(10):1109-1125. DOI: 10.1080/14656566.2018.1494154. View

2.
Cooper T, Chen J, Wiffen P, Derry S, Carr D, Aldington D . Morphine for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017; 5:CD011669. PMC: 6481499. DOI: 10.1002/14651858.CD011669.pub2. View

3.
Ghazizadeh S, Nikzad M . Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol. 2004; 104(5 Pt 1):922-5. DOI: 10.1097/01.AOG.0000141441.41178.6b. View

4.
Schultz D . Inferior hypogastric plexus blockade: a transsacral approach. Pain Physician. 2007; 10(6):757-63. View

5.
Dessie S, Von Bargen E, Hacker M, Haviland M, Elkadry E . A randomized, double-blind, placebo-controlled trial of onabotulinumtoxin A trigger point injections for myofascial pelvic pain. Am J Obstet Gynecol. 2019; 221(5):517.e1-517.e9. PMC: 9539654. DOI: 10.1016/j.ajog.2019.06.044. View